Live Breaking News & Updates on Galecto inc

Stay informed with the latest breaking news from Galecto inc on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Galecto inc and stay connected to the pulse of your community

Research Analysts Offer Predictions for Galecto, Inc.'s FY2028 Earnings (NASDAQ:GLTO)

Research Analysts Offer Predictions for Galecto, Inc.'s FY2028 Earnings (NASDAQ:GLTO)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Leerink-partnrs , Nasdaq , Susquehanna-international-group , Charles-schwab-investment-management-inc , Galecto-inc , Renaissance-technologies , Simplex-trading , Galecto-company-profile , Belvedere-trading , Free-report , Get-free-report , International-group

GB2064 Displays Preliminary Efficacy, Tolerability in Myelofibrosis

The potential first-in-class, oral, lysyl oxidase-like 2 inhibitor GB2064 displayed efficacy with a generally acceptable tolerability profile in the treatment of patients with myelofibrosis.

London , City-of , United-kingdom , Claire-harrison , Hanst-schambye , Dynamic-international-prognostic-scoring , Galecto-inc , Safety-review-committee , Total-symptom-score , Myeloma , Phase-2a-mylox-1-trial-nct04679870- , Lysyl-oxidase-like-2-inhibitor

Galecto (NASDAQ:GLTO) Trading Up 1.8%

Galecto, Inc. (NASDAQ:GLTO – Get Free Report)’s stock price was up 1.8% during mid-day trading on Monday . The stock traded as high as $0.73 and last traded at $0.72. Approximately 579,002 shares traded hands during mid-day trading, an increase of 89% from the average daily volume of 307,100 shares. The stock had previously closed […]

Simplex-trading , Renaissance-technologies , Belvedere-trading , Nasdaq , Susquehanna-international-group , Galecto-inc , Get-free-report , Stock-down , International-group , Galecto-daily , Galecto

Nike, AAR And 3 Stocks To Watch Heading Into Friday - Galecto (NASDAQ:GLTO), AAR (NYSE:AIR)

With U.S. stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows:

United-states , Marathon-petroleum , Rocket-lab , Marathon-petroleum-corporation , Galecto-inc , Rocket-lab-united-states-inc , Nike-inc , Lab-united-states , Maryann-mannen , John-quaid , Executive-vice-president

Galecto Inc. (GLTO) Reports Topline Results from MYLOX-1 Trial Demonstrated Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis

Galecto Inc. (GLTO) Reports Topline Results from MYLOX-1 Trial Demonstrated Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hans-schambye , Claire-harrison , Nasdaq , Galecto-inc , Safety-review-committee , Total-symptom-score , Chief-executive-officer ,

Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis

Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Boston , Massachusetts , United-states , Hans-schambye , Ashleyr-robinson , Claire-harrison , Jon-freve , Exchange-commission , Nasdaq , Safety-review-committee , Galecto-inc , Demonstrate-reduction

Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis

The Entire Business World on a Single Page with the Web's Most Comprehensive One-Stop Finance News Hub.

Boston , Massachusetts , United-states , Galecto-inc ,

GALLANT-1: GB1211 Galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) -October 23, 2023 at 08:28 am EDT

GALLANT-1: GB1211 Galectin-3 inhibitor plus atezolizumab for first line treatment in patients

...

Badalona , Comunidad-autonoma-de-cataluna , Spain , France , Valencia , Carabobo , Venezuela , Germany , Denmark , Poland , Burgundy , France-general-

Brokerages Set Galecto, Inc. (NASDAQ:GLTO) Price Target at $7.60

Shares of Galecto, Inc. (NASDAQ:GLTO – Get Free Report) have received a consensus rating of “Hold” from the seven research firms that are currently covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price objective […]

Leerink-partnrs , Orbimed-advisors-llc , Belvedere-trading , Galecto-inc , Charles-schwab-investment-management-inc , Nasdaq , Renaissance-technologies , Blackrock-inc , Geode-capital-management , Get-free-report , Capital-management , Schwab-investment-management

Galecto Announces Plans to Explore Strategic Alternatives

BOSTON, Sept. 26, 2023 -- Galecto, Inc. , a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it has completed a...

Boston , Massachusetts , United-states , Hans-schambye , Jon-freve , Ashleyr-robinson , Globenewswire-inc , Nasdaq , Galecto-inc , Exchange-commission , Private-securities-litigation-reform-act , Annual-report